Next Article in Journal
Probing Protein-Protein Interactions Using Asymmetric Labeling and Carbonyl-Carbon Selective Heteronuclear NMR Spectroscopy
Previous Article in Journal
Preparation of Silica Aerogels by Ambient Pressure Drying without Causing Equipment Corrosion
Previous Article in Special Issue
Measurement of Cyanine Dye Photobleaching in Photosensitizer Cyanine Dye Conjugates Could Help in Optimizing Light Dosimetry for Improved Photodynamic Therapy of Cancer
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessFeature PaperReview
Molecules 2018, 23(8), 1936; https://doi.org/10.3390/molecules23081936

Use of Cyclodextrins in Anticancer Photodynamic Therapy Treatment

1
Laboratoire de Chimie Phusique Macromoléculaire, Université de Lorraine, CNRS, LCPM, F-54000 Nancy, France
2
Laboratoire Réactions et Génie des Procédés, Université de Lorraine, CNRS, LRGP, F-54000 Nancy, France
*
Author to whom correspondence should be addressed.
Received: 28 June 2018 / Revised: 19 July 2018 / Accepted: 28 July 2018 / Published: 2 August 2018
(This article belongs to the Special Issue Advances in Photodynamic Therapy 2018)

Abstract

Photodynamic therapy (PDT) is mainly used to destroy cancerous cells; it combines the action of three components: a photoactivatable molecule or photosensitizer (PS), the light of an appropriate wavelength, and naturally occurring molecular oxygen. After light excitation of the PS, the excited PS then reacts with molecular oxygen to produce reactive oxygen species (ROS), leading to cellular damage. One of the drawbacks of PSs is their lack of solubility in water and body tissue fluids, thereby causing low bioavailability, drug-delivery efficiency, therapeutic efficacy, and ROS production. To improve the water-solubility and/or drug delivery of PSs, using cyclodextrins (CDs) is an interesting strategy. This review describes the in vitro or/and in vivo use of natural and derived CDs to improve antitumoral PDT efficiency in aqueous media. To achieve these goals, three types of binding modes of PSs with CDs are developed: non-covalent CD–PS inclusion complexes, covalent CD–PS conjugates, and CD–PS nanoassemblies. This review is divided into three parts: (1) non-covalent CD-PS inclusion complexes, covalent CD–PS conjugates, and CD–PS nanoassemblies, (2) incorporating CD–PS systems into hybrid nanoparticles (NPs) using up-converting or other types of NPs, and (3) CDs with fullerenes as PSs. View Full-Text
Keywords: cylodextrin; photosensitizer; photodynamic therapy; cancer; inclusion complex; conjugate; nanoassembly; nanoparticle; porphyrinoid; fullerene cylodextrin; photosensitizer; photodynamic therapy; cancer; inclusion complex; conjugate; nanoassembly; nanoparticle; porphyrinoid; fullerene
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Ben Mihoub, A.; Larue, L.; Moussaron, A.; Youssef, Z.; Colombeau, L.; Baros, F.; Frochot, C.; Vanderesse, R.; Acherar, S. Use of Cyclodextrins in Anticancer Photodynamic Therapy Treatment. Molecules 2018, 23, 1936.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top